9 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $502M | -$733M | 95.8% | -104.2% | -$447M | $2.0B | $570M |
| 2024 | $222M | -$543M | 98.3% | -267.2% | -$522M | $437M | $681M |
| 2023 | $9M | -$653M | 73.7% | -6528.8% | -$529M | $446M | $376M |
| 2022 | $78M | -$485M | 95.6% | -659.6% | -$424M | $431M | $377M |
| 2021 | $70M | -$586M | 95.5% | -827.1% | -$511M | $431M | $394M |
| 2020 | $8M | -$505M | 0.0% | -5752.0% | -$407M | $94M | $356M |
| 2019 | $41M | -$289M | 0.0% | -656.4% | -$256M | $95M | $364M |
| 2018 | — | -$169M | — | — | -$139M | $55M | $436M |
| 2017 | — | -$44M | — | — | -$41M | — | $92M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $195M | -$167M | 94.9% | -54.5% | -$197M | $2.7B | $880M |
| Dec '25 | $154M | -$195M | 94.7% | -90.5% | -$56M | $2.0B | $570M |
| Sep '25 | $121M | -$185M | 94.6% | -120.3% | -$110M | $2.0B | $643M |
| Jun '25 | $111M | -$184M | 96.7% | -121.4% | -$81M | $0 | $749M |
| Mar '25 | $117M | -$170M | 97.7% | -89.5% | -$199M | $0 | $541M |
| Dec '24 | $6M | -$267M | 64.6% | -3842.7% | -$195M | $437M | $681M |
| Sep '24 | $3M | -$164M | 78.1% | -7018.7% | -$181M | $436M | $266M |
| Jun '24 | $2M | -$76M | 72.4% | -8096.8% | $75M | $435M | $408M |
| Mar '24 | $211M | -$36M | 99.7% | 0.2% | -$220M | $435M | $475M |
| Dec '23 | $2M | -$170M | 65.7% | -10167.1% | -$125M | $446M | $376M |
| Sep '23 | $4M | -$179M | 85.4% | -3854.6% | -$146M | $442M | $505M |
| Jun '23 | $2M | -$161M | 63.5% | -8903.0% | -$114M | $440M | $302M |
| Mar '23 | $2M | -$143M | 64.3% | -6909.3% | -$144M | $436M | $407M |
| Dec '22 | $2M | -$141M | 65.4% | -6910.8% | -$94M | $431M | $377M |
| Sep '22 | $338000 | -$140M | -118.6% | -38200.0% | -$136M | — | $483M |
| Jun '22 | $74M | -$3M | 99.1% | -108.7% | -$33M | — | $470M |
| Mar '22 | $2M | -$201M | 0.0% | -10252.5% | -$161M | $434M | $372M |
| Dec '21 | $13M | -$152M | 0.0% | -1285.2% | -$136M | $431M | $394M |
| Sep '21 | $2M | -$161M | 0.0% | -6377.9% | -$128M | $103M | $180M |
| Jun '21 | $54M | -$102M | 0.0% | -174.0% | -$94M | $103M | $378M |
How the market has priced BBIO against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Bridgebio Pharma, Inc.'s revenue has grown 127.4% per year. These are computed facts, not advice.
As of FY2025, Bridgebio Pharma, Inc. reported $2.0B of total debt against $570M of cash; operating income covered interest expense -9.9×.
In FY2025, gross margin was 95.8%, operating margin -104.2%, and net margin -146.0%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.